Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects
Authors:
- 25 February 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5291-5308
Abstract
Tropomyosin receptor kinase (TRK) is an important therapeutic target for tumors driven by NTRK gene fusions. However, the clinically approved TRK inhibitors, including Larotrectinib and Entrectinib, are limited by insufficient efficacy and resistance due to kinase mutations. Here, we report DZX19 (C02), a novel phenyl thiophene-3-carboxamide TRK inhibitor developed via a pharmacophore-guided scaffold-hopping approach combined with structure-based design, based on the key binding features of Entrectinib. DZX19 demonstrated stronger in vitro activity and an improved resistance profile against Entrectinib-resistant TRKA mutants, including G595R, F589L, and G667C. In the TPM3-NTRK1 fusion-positive Km-12 cell line, DZX19 induced G1 arrest, promoted apoptosis, and suppressed TRK downstream signaling. DZX19 displayed excellent plasma stability and moderate microsomal stability. In the Km-12 xenograft model, DZX19 significantly suppressed tumor growth. These results indicate that DZX19 serves as a novel TRK-targeting lead compound for further investigation.Keywords
This publication has 23 references indexed in Scilit:
- Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK InhibitorsEuropean Journal of Medicinal Chemistry, 2025
- Discovery, Optimization, and Evaluation of Novel Pyridin-2(1H)-one Analogues as Potent TRK Inhibitors for Cancer TreatmentJournal of Medicinal Chemistry, 2024
- Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of CancerJournal of Medicinal Chemistry, 2021
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trialsThe Lancet Oncology, 2020
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenNew England Journal of Medicine, 2018
- Neurotrophic Factors: An Overview2017
- A facile and practical one-pot synthesis of multisubstituted 2-aminothiophenes via imidazole-catalyzed Gewald reactionTetrahedron, 2011
- New conditions for the synthesis of thiophenes via the Knoevenagel/Gewald reaction sequence. Application to the synthesis of a multitargeted kinase inhibitorTetrahedron, 2006
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Molecular Basis of Neurotrophin−Receptor InteractionsJournal of Medicinal Chemistry, 2003